Table 1.
Characteristics of included studies.
| References | Nature of Article | Country | Sample Size (n) |
Intervention |
Control |
Experience of Endoscopist | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Position | Age (years) (Mean ± SD) | Type of Analgesia (Dose) | Position | Age (years) (Mean ± SD) | Type of Analgesia (Dose) | |||||
| Klare et al,24 2015 |
FT | Germany | 412 | SP | 56.8 ± 15.4 | Propofol (180 mg) | LLP | 54.9 ± 17.1 | Propofol (200 mg) | NA |
| Zhao et al,25 2019 |
FT | China | 347 | SP | 51.5 ± 14.3 | NA | LLP | 52.8 ± 14.6 | NA | 1 (<1000 Endoscopes) 1 (1000–3000 Endoscopes) 1 (>3000 Endoscopes) |
| Uddin et al,27 2014 |
FT | India | 101 | PP | 62.5 | Midazolam (3.0 mg) Fentanyl (71.5 μg) Meperidine (58.3 mg) None |
LLP | 60.7 | Midazolam (3.1 mg) Fentanyl (62.9 μg) Meperidine (50 mg) None |
3 Experienced |
| Vergis et al,28 2018 |
FT | United Kingdom | 174 | PP | 59 | Midazolam (2 mg) Fentanyl (50 μg) |
LLP | 55 | Midazolam (2 mg) Fentanyl (50 μg) |
1 (>200 Endoscopes) |
| De Silva et al,26 2010 |
FT | Sri Lanka | 150 | PP | 50 ± 17.91 | Midazolam (2.5 mg) Peptidine (25 mg) |
LLP | 55 ± 18.24 | Midazolam (2.5 mg) Peptidine (25 mg) |
9 (<200 Endoscopes) |
| Mocanu et al,30 2017 |
AB | Spain | 188 | RL | 61 | Midazolam (1.04 mg) Peptidine (25 mg) |
LLP | 64 | Midazolam (1.09 mg) Peptidine (25 mg) |
5 (200–500 Endoscopes) |
| Gonzalez et al,29 2017 |
AB | Spain | 179 | RL | NA | NA | LLP | NA | NA | 126 (500–5000 Endoscopes) |
RCT: Randomized control trials; LLP: Left Lateral Position; PP: Prone Position; SP: Supine Position; PP: Prone Position; NA: Datasets were not provided by publication; FT: Full Text Articles; AB: Abstract.